EW News and Press, Edwards Lifesciences Corporation From 08/12/19

Introduction I've only had time to do three Q2 articles on biotechs, including Edwards ( EW ) in that category. In this article, I'll therefore present some comments on stocks which I have not written about in a few months or longer, as well a brief update on my largest biotech holding, Merc...

Introduction As explained in previous SA articles ( 17 Healthcare Companies To Consider Based On Patent... , 40% Return In ~4 Months With Our IP Selected Health... , In Which Company Should You Invest In, Taking Into ... , In Which Field/Sub-Field Should You Invest In, Taki... , Patent...

Introduction We present here some results of a study on U.S. listed companies in the healthcare sector (Nasdaq, NYSE and Amex) based on their patent activity based on PCT (Patent Cooperation Treaty) patent applications administered by the World Intellectual Property Office (WIPO). We have sh...

Being on the sidelines for now does not mean you are permanently passive Chartists count closing prices, so let's see if we close below 2,950. The sell-off yesterday could not break 2,950, but now in the premarket, the S&P futures are 2,940ish. If the S&P closes decisively lower th...

All Hail the Breakout Kings! I suspect there will be many more. The bar for success is very low, since we are expecting a nearly 50% deceleration in GDP in Q2, and all the economic negative news from China. I suspect with all the good numbers being reported, we may just run above 2% for GDP....

Jounce Therapeutics (NASDAQ: JNCE )  +34%  on revised Celgene collaboration . More news on: Jounce Therapeutics, Inc., Teradyne, Inc., Vislink Technologies, Inc., Stocks on the move, Read more ...

Gainers: JNCE   +42.8% . SNAP   +11.1% . EW   +10.5% . MANH   +9.6% . TXN   +5.9% . More news on: Jounce Therapeutics, Inc., Snap Inc., Edwards Lifesciences Corporation, Stocks on the move, Read more ...

Edwards Lifesciences (NYSE: EW ) Q2 results ($M): Sales: 1,086.9 (+15.2%); Transcatheter Aortic Valve Replacement: 677.7 (+16.0%); Surgical Structural Heart: 217.8 (+14.5%); Critical Care: 184.4 (+9.4%). More news on: Edwards Lifesciences Corporation, Healthcare stocks news, Earnings new...

Edwards Lifesciences (NYSE: EW ): Q2 Non-GAAP EPS of $1.38 beats by $0.05 ; GAAP EPS of $1.14 misses by $0.18 . More news on: Edwards Lifesciences Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

IRVINE, Calif. , July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2019. Sec...